Financings Of The Fortnight Notices Autumn Coincides With Increase In Option Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q3 2012
Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.
Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.
Series A Financing For Annovation Includes Potential Buyout By TMC
The newest company created under the Atlas Venture Development Corp. model, Annovation, will develop a next-generation anesthetic through proof-of-concept, with investor The Medicines Co. holding an option to acquire the new company.